Recent Updates
Recently added Catalysts
CNTA Positive Sentiment Score: 65/100

Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference

Thursday, February 22, 2024 1 min read
Key Takeaway: Centessa Pharmaceuticals plc announced its participation in TD Cowen’s 44th Annual Health Care Conference in Boston, scheduled for March 5th. The management team will engage in a fireside chat, providing insights into the company's ongoing projects and pipeline. The event aims to increase visibility and foster interaction with potential investors. Centessa focuses on developing innovative treatments, including programs for hemophilia and narcolepsy.

Market Sentiment Analysis

POSITIVE FACTORS

  • Centessa Pharmaceuticals is actively participating in a major healthcare conference.
  • The company showcases confidence in its pipeline and capabilities.
  • The event may enhance visibility and investor interest in Centessa's advancements.

Full Press Release Details

BOSTON and LONDON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in TD Cowen’s 44th Annual Health Care Conference in Boston, MA. A fireside chat is scheduled for Tuesday, March 5th at 2:50 PM ET.
The live audio webcast of this event, as well as an archived recording, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/events-presentations.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients. Our most advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders and an immuno-oncology program focused on our LockBody® technology platform. We operate with the conviction that each one of our programs has the potential to change the current treatment paradigm and establish a new standard of care. For more information, visit www.centessa.com, which does not form part of this release.
Kristen K. Sheppard, Esq.
SVP of Investor Relations
investors@centessa.com

Related Links

Frequently Asked Questions

What event will Centessa Pharmaceuticals participate in?

Centessa Pharmaceuticals will take part in TD Cowen’s 44th Annual Health Care Conference.

When is the Centessa Pharmaceuticals fireside chat scheduled?

The fireside chat is set for Tuesday, March 5th at 2:50 PM ET.

Where can I find the webcast of the event?

The live audio webcast and archived recording will be available on their website.

What are the main programs of Centessa Pharmaceuticals?

Their key programs focus on hemophilia, narcolepsy, and immuno-oncology.

Who is the contact person for investor relations?

Kristen K. Sheppard is the Senior Vice President of Investor Relations.

Tags: CNTA Viatris Investor Conferences Healthcare Centessa Pharmaceuticals TD Cowen healthcare conference investor relations innovative medicines
Last updated: Feb 22, 2024